JOSH'S STORY
In February of 2021, Josh’s parents noticed he was getting very pale. What was originally thought to...
Read MoreRhabdomyosarcoma is the third most prevalent children’s cancer and approximately 3% of children’s cancers are rhabdomyosarcomas with 250 US and 60 UK children diagnosed a year (Ognjanovic et al., 2009; Macmillan Cancer Support, 2018). A recent paper (Do et al., 2016) has identified several phenothiazinyl chalcones which are cytotoxic to rhabdomyosarcoma cells. Previous work (Ducki et al., 1998) has shown that modifications to the double bond of chalcones can markedly improve (20x) the cytotoxic action of chalcones to cancer cell lines. This project aims to similarly modify the phenothiazinyl derived chalcones and identify a suitable candidate for pre-clinical evaluation as an agent to combat rhabdomyosarcoma.
Grant Award – Kidscan Student Placement (2018 – 2019)
Funding Award – £1000.00
Funding Awarded to – Dr John Hadfield
Research Location – University of Salford
Lead Researcher – Dr John Hadfield
In February of 2021, Josh’s parents noticed he was getting very pale. What was originally thought to...
Read MoreWhat a whopper of a night - Friday 20th May, our ambassador Isla's mum Jill and family hosted...
Read MoreWe want to say a huge thank you to Lee Mossop, former Captain of RFL Salford Red...
Read More